Vnitr Lek 2024, 70(1):22-27 | DOI: 10.36290/vnl.2024.004

Clinical manifestations of chronic hypoparathyroidism

Roman Králik, Martin Kužma, Juraj Payer
V. interná klinika UNB a LFUK Bratislava

Hypoparathyroidism is a rare disease, which is unique among endocrine diseases because of the fact, that it is the only disease with a hormonal deficit not treated with hormonal supplementation as the standard mode of therapy. Conventional therapy is based on oral calcium and vitamin D substitution. This treatment is often complicated, especially in adjusting the dosage of calcium and vitamin D supplementation and also because of the numerous complications affecting virtualy every system in the human body. Generally, these complications are divided into skeletal and nonskeletal. Changes in bone mineral density and microarchitecture are the main skeletal complications, and they may lead to an increased risk of fractures. Kidney function progressively declines over the course of hypoparathyroidism, sometimes leading to end stage kidney disease. Morphological changes of the kidneys are also present in the form of nephrocalcinosis and nephrolithiasis. The cardiovascular system is especially susceptible to rapid changes in serum calcium levels, that can lead to malign arrhytmias. Paresthesias, seizures, bronchospasms or laryngospasms are associated with low calcium levels as well. The function of immune system is impaired in hypoparathyroidism, resulting in higher rate of infections in these patients, requiring hospitalisation more often compared to patients with adequate parathyroid function. Psychological changes are also well documented in hypoparathyroidism and combined with the other aforementioned complications, significantly reduce the quality of life of the patients suffering from this disease. Recombinant parathormone treatment is a promising treatment option of hypoparathyroidism. The efficacy of this therapy is documented by it´s ability to stabilize serum calcium levels, calciura and phosphatemia. Parathormone treatment also reduces the worsening of renal function and reverses changes in bone structure present in hypoparathyroidism. Unfortunately, this therapy is not readily available.

Keywords: complications, hypoparathyidism, therapy.

Accepted: February 9, 2024; Published: February 26, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Králik R, Kužma M, Payer J. Clinical manifestations of chronic hypoparathyroidism. Vnitr Lek. 2024;70(1):22-27. doi: 10.36290/vnl.2024.004.
Download citation

References

  1. Siraj N, Hakami Y, Khan A. Medical hypoparathyroidism. Endocrinol Metab Clin North Am. 2018;47(4):797-808. Go to original source... Go to PubMed...
  2. Hannan FM, Babinsky VN, Thakker RV. Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis. J Mol Endocrinol. 2016;57(3):R127-R142. Go to original source... Go to PubMed...
  3. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015;116(1-2):4-12. Go to original source... Go to PubMed...
  4. Abraham MB, Li D, Tang D, et al. Short stature and hypoparathyroidism in a child with Kenny-Caffey syndrome type 2 due to a novel mutation in FAM111A gene. Int J Pediatr Endocrinol. 2017;2017:1. Go to original source... Go to PubMed...
  5. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359(4):391-403. Go to original source... Go to PubMed...
  6. Melmed S, Auchus J, Goldfine A, et al. Parathyroid hormone, Williams Textbook of Endocrinology 14th ed. Elsevier: 2019 ISBN: 978-0-323-55596-8.
  7. Kužma M, Jackuliak P, Killinger Z, Payer J. Parathyroid Hormone-Related Changes of Bone Structure. Physiol Res. 2021 doi: 10.33549/physiolres.934779. Go to original source... Go to PubMed...
  8. Meiheng Sun, et al. Disorders of Calcium and Phosphorus Metabolism and the Preomics/Metabolomics-Based Research. Front. Cell Dev. Biol., 10 September 2020 Sec. Molecular and Cellular Pathology Volume 8 - 2020. Go to original source...
  9. Kršek M, et al. Doporučený postup české endokrinologické společnosti pro diagnostiku a léčbu primární hyperparatyreózy a hypoparatyreózy. Vnitř Lék. 2021;67(Suppl. A).
  10. Lazúrová I, Payer J, et al. Štandardné diagnostické a terapeutické postupy v endokrinológii. II. Vydanie. Vienala: Košice(2014) ISBN: 978-80-8126-089-6.
  11. Silva BC. Skeletal and nonskeletal consequences of hypoparathyroidism. Arch Endocrinol Metab. 2022. doi: 10.20945/2359-3997000000553. Go to original source... Go to PubMed...
  12. Rubin MR, Bone Mishaela R. Rubin. Skeletal Manifestations of Hypoparathyroidism, Bone, 2019;120:548-555, ISSN 8756-3282. Go to original source... Go to PubMed...
  13. Rubin MR, Manavalan JS, Dempster DW, et al. Parathyroid Hormone Stimulates Circulating Osteogenic Cells in Hypoparathyroidism, The Journal of Clinical Endocrinology & Metabolism, 2011;96:176-186, https://doi.org/10.1210/jc.2009-2682. Go to original source... Go to PubMed...
  14. Aline G, Rubin MR, et al. Circulating Sclerostin in Disorders of Parathyroid Gland Function, The Journal of Clinical Endocrinology & Metabolism. 2011;96: 3804-3810, https://doi.org/10.1210/jc.2011-0566. Go to original source... Go to PubMed...
  15. Rubin MR, Dempster DW, et al. Three dimensional cancellous bone structure in hypoparathyroidism, Bone. 2010;46:190-195, ISSN 8756-3282 Go to original source... Go to PubMed...
  16. Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008;23(12):2018-2024. Go to original source... Go to PubMed...
  17. Langdahl BL, Mortensen L, Vesterby A, et al. Bone histomor-phometry in hypoparathyroid patients treated with vitamin D, Bone. 1996;18:103-108. Go to original source... Go to PubMed...
  18. Abugassa S, Nordenström J, Eriksson S, Sjödén G. (1993). Bone mineral density in patients with chronic hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 76(6), 1617-1621. doi:10.1210/jcem.76.6.8501170. Go to original source... Go to PubMed...
  19. Chen Q, Kaji H, Iu MF, et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 2003;88(10):4655-8. Go to original source... Go to PubMed...
  20. Cusano NE, Nishiyama KK, Zhang C, et al. Noninvasive Assessment of Skeletal Microstructure and Estimated Bone Strength in Hypoparathyroidism. J Bone Miner Res. 2016;31(2):308-316. Go to original source... Go to PubMed...
  21. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. The Epidemiology of Nonsurgical Hypoparathyroidism in Denmark: A Nationwide Case Finding Study. J Bone Miner Res. 2015;30(9):1738-1744. Go to original source... Go to PubMed...
  22. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Postsurgical hypoparathyroidism--risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29(11):2504-2510. Go to original source... Go to PubMed...
  23. Cipriani C, Minisola S, Bilezikian JP, et al. Vertebral Fracture Assessment in Postmenopausal Women With Postsurgical Hypoparathyroidism. J Clin Endocrinol Metab. 2021;106(5):1303-1311. Go to original source... Go to PubMed...
  24. Pal R, Bhadada SK, Mukherjee S, Banerjee M, Kumar A. Fracture risk in hypoparathyroidism: a systematic review and meta-analysis. Osteoporos Int. 2021;32(11):2145-2153 Go to original source... Go to PubMed...
  25. Starr JR, Tabacco G, Majeed R, Omeragic B, Bandeira L, Rubin MR. PTH and bone material strength in hypoparathyroidism as measured by impact microindentation. Osteoporos Int. 2020;31(2):327-333. Go to original source... Go to PubMed...
  26. Sakane EN, Camargo VC, Lazaretti-Castro M, Maeda SS Predictors of Poor Bone Microarchitecture Assessed by Trabecular Bone Score (TBS) in Postsurgical Hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism. 2019. doi:10.1210/jc.2019-00698 Go to original source... Go to PubMed...
  27. Mannstadt M, Clarke BL, Bilezikian JP, et al. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. J Clin Endocrinol Metab. 2019 Nov 1;104(11):5136-5147. doi: 10.1210/jc.2019-01010. Go to original source... Go to PubMed...
  28. Gosmanova EO, Houillier P, Rejnmark L, et al. Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism. Rev Endocr Metab Disord. 2021 Jun;22(2):297-316. doi: 10.1007/s11154-020-09613-1. Go to original source... Go to PubMed...
  29. Hadker N, Egan J, Sanders J, et al. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. Endocr Pract. 2014;20(7):671-679. Go to original source... Go to PubMed...
  30. Meola A, Vignali E, Matrone A, Cetani F, Marcocci C. Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Investig. 2018;41(10):1221-1226. Go to original source... Go to PubMed...
  31. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28(11):2277-2285 Go to original source... Go to PubMed...
  32. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res. 2015;30(9):1738-1744. Go to original source... Go to PubMed...
  33. Lopes MP, Kliemann BS, Bini IB, et al. Hypoparathyroidism and pseudohypoparathyroidism: etiology, laboratory features and complications. Arch Endocrinol Metab. 2016;60(6):532-6. Go to original source... Go to PubMed...
  34. Gosmanova EO, Chen K, Rejnmark L, et al. Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. Adv Ther. 2021 Apr;38(4):1876-1888. doi: 10.1007/s12325-021-01658-1. Go to original source... Go to PubMed...
  35. Underbjerg L, Sikjaer T, Rejnmark L. Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. J Bone Miner Res. 2018;33:822-831. Go to original source... Go to PubMed...
  36. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:4507-4514. Go to original source... Go to PubMed...
  37. Vadiveloo T, Donnan PT, Leese CJ, Abraham KJ, Leese GP. Increased mortality and morbidity in patients with chronic hypoparathyroidism: a population-based study. Clin Endocrinol. 2019;90:285-292. Go to original source... Go to PubMed...
  38. Cusano NE, Bilezikian JP. Signs and Symptoms of Hypoparathyroidism. Endocrinol Metab Clin North Am. 2018;47(4):759-770. Go to original source... Go to PubMed...
  39. Saini N, Mishra S, Banerjee S, Rajput R. Hypocalcemic cardiomyopathy: a rare presenting manifestation of hypoparathyroidism. BMJ Case Rep. 2019;12. Go to original source... Go to PubMed...
  40. Kim SH, Rhee Y, Kim YM, Won YJ, Noh J, Moon H, et al. Prevalence and complications of nonsurgical hypoparathyroidism in Korea: A nationwide cohort study. PLoS One. 2020. Go to original source...
  41. Anderson JJ, Klemmer PJ. Risk of high dietary calcium for arterial calcification in older adults. Nutrients. 2013 Sep 30;5(10):3964-74. doi: 10.3390/nu5103964. Go to original source... Go to PubMed...
  42. Morelli MB, Santulli G, Gambardella J. Calcium supplements: Good for the bone, bad for the heart? A systematic updated appraisal. Atherosclerosis. 2020 Mar;296:68-73. doi: 10.1016/j.atherosclerosis.2020.01.008. Go to original source... Go to PubMed...
  43. Další literatura u autora a na www.casopisvnitrnilekarstvi.cz
  44. Zavatta G, Clarke BL. Basal ganglia calcification in hypoparathyroidism and pseudohypoparathyroidism: local and systemic metabolic mechanisms. J Endocrinol Invest. 2021;44(2):245-253. Go to original source... Go to PubMed...
  45. Oh-hora M, Rao A. Calcium signaling in lymphocytes. Curr Opin Immunol. 2008;20(3):250-258. Go to original source... Go to PubMed...
  46. Puliani G, Hasenmajer V, Sciarra F, et al. Impaired Immune Function in Patients With Chronic Postsurgical Hypoparathyroidism: Results of the EMPATHY Study. J Clin Endocrinol Metab. 2021. Go to original source... Go to PubMed...
  47. Brod M, Waldman LT, Smith A, Karpf D. Assessing the Patient Experience of Hypoparathyroidism Symptoms: Development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom) Patient. 2020. Go to original source...
  48. Brod M, Waldman LT, Smith A, Karpf D. Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPES-Impact) Qual Life Res. 2021. Go to original source...
  49. Arneiro AJ, Duarte BCC, Kulchetscki RM, et al. Self-report of psychological symptoms in hypoparathyroidism patients on conventional therapy. Arch Endocrinol Metab. 2018. Go to original source...
  50. Khan AA, Rubin MR, Schwarz P, et al. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. J Bone Miner Res. 2023 Jan;38(1):14-25. doi: 10.1002/jbmr.4726. Go to original source... Go to PubMed...
  51. Mannstadt M, Clarke BL, Bilezikian JP, et al. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. J Clin Endocrinol Metab. 2019 Nov 1;104(11):5136-5147. doi: 10.1210/jc.2019-01010. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.